Lucinactant | |
---|---|
Trade Name | Surfaxin |
Orphan Indication | Acute respiratory distress syndrome |
USA Market Approval | USA |
USA Designation Date | 1995-07-17 00:00:00 |
Sponsor | Windtree Therapeutics, Inc.;2600 Kelly Road, Suite 100;Warrington, Pennsylvania, 18976 |
Related Access Program
SynCore Biotechnology Co., Ltd. – Malignant Solid Tumour
University of California, San Francisco – Anemia Due to Intrinsic Red Cell Abnormality
Joanne Kurtzberg, MD – Hematologic Malignancies
European Institute for Evidence Based Osteopathic Medicine – The Focus of the Study is to Provide a Guideline on Osteopathic Approach in Treating Hospitalized Newborns.
Xiaofan Zhu – Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.
Kochi University – Both Benign and Malignant Liver Mass
Eisai Inc. – Seizure Disorder Generalized Tonic Clonic
Ariad Pharmaceuticals – Advanced Malignancies
M.D. Anderson Cancer Center – Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
M.D. Anderson Cancer Center – Malignant Neoplasms of Digestive Organs